In its pipeline of drugs, the pharmaceutical company astrazeneca has the drug faslodex in phase 3 clinical trials for the treatment of firstline advanced breast cancer.The company records show that it is due to get a marketing authorisation for this drug Q4 2009 which is this winter.
Faslodex facts
This is what is classified as an ostrogen receptor antagonist and has shown very promising results its due for a 2010 release.......ask your GP or go to
http://www.faslodex.net/
No comments:
Post a Comment